PET image-processing software that reduces image noise while preserving the original images for clinical review.
Clinical role
SubtleHD-PET 1.x is image-processing software that reduces PET or PET/CT/PET-MR image noise for images acquired with any radiotracer within the labeled workflow.
Images and patients
PET/SPECT/Nuclear Medicine · Whole body and the body regions represented in PET studies
Key limitation
Original and enhanced images must be distinguished, and the physician remains responsible for clinical interpretation.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?It processes PET, PET/CT, or PET/MR images to reduce image noise.
Which scans and patients is it intended for?It is for PET studies across the body, including PET/CT or PET/MR images acquired with any radiotracer in the labeled workflow.
Who uses it?Qualified healthcare professionals trained to interpret PET, nuclear-medicine, and CT information use the processed images.
What does the software produce, and what must the clinician do?It returns enhanced standard image files (DICOM) while retaining the originals. The physician must distinguish the image types and make the clinical interpretation.
What is its most important limitation?It processes images but does not control the scanner, and clinical interpretation remains with the physician.
Clinical takeaway. SubtleHD-PET is an image-processing tool, not scanner control. The clinician must keep original and enhanced images distinct when interpreting the study.
Evidence takeaway. The FDA material describes the labeled intended use and submission-level verification for this release. It does not establish product-wide clinical sensitivity, specificity, or independent clinical outcome evidence.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
SubtleHD-PET 1.x is image-processing software that reduces PET or PET/CT/PET-MR image noise for images acquired with any radiotracer within the labeled workflow.
SubtleHD-PET 1.x is image-processing software that reduces PET or PET/CT/PET-MR image noise for images acquired with any radiotracer within the labeled workflow.
Anatomical CT and functional nuclear-medicine images, attenuation correction, reconstructions, or processing outputs described in the exact FDA labeling.
The software processes images and does not control the scanner; original and enhanced images must be distinguished, and clinical interpretation remains with the physician.
The exact FDA document reports software verification and validation, a performance validation on 203 studies (PET-only model) and 122 studies (PET/CT model), and a retrospective reader study. All primary performance endpoints passed; average PSNR improvement in the default configuration was 1.935 dB for the PET-only model. Board-certified nuclear medicine physicians evaluated image quality/diagnostic confidence, artifacts, and false positives and negatives using lesion counts; the reader study tests passed. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Software Verification and Validation testing (unit, integration, and system testing) to demonstrate that software requirements are implemented. These tests passed." … "In total 203 studies were used to validate the PET-only model and 122 studies used to validate the PET/CT model acceptance criteria". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports software verification and validation, a performance validation on 203 studies (PET-only model) and 122 studies (PET/CT model), and a retrospective reader study. All primary performance endpoints passed; average PSNR improvement in the default configuration was 1.935 dB for the PET-only model. Board-certified nuclear medicine physicians evaluated image quality/diagnostic confidence, artifacts, and false positives and negatives using lesion counts; the reader study tests passed. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Software Verification and Validation testing (unit, integration, and system testing) to demonstrate that software requirements are implemented. These tests passed." … "In total 203 studies were used to validate the PET-only model and 122 studies used to validate the PET/CT model acceptance criteria". Read from the exact FDA decision document on 2026-11-14.
No exact-product, version-specific sensitivity endpoint was established for this submission in the evidence set.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No exact-product, version-specific specificity endpoint was established for this submission in the evidence set.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K254013 FDA evidence package for SubtleHD-PET (1.x)
DesignFDA submission-level decision material with device, software, performance, safety, and/or usability verification as applicable; not independent clinical validation.
PopulationPopulation and workflow are limited to the exact FDA labeling summarized for this submission.
Scopeexact submission
Tested versionExact FDA submission release; version not separately stated in the public decision material
IndependenceSponsor or vendor study
K254013
Evidence submitted for the exact FDA decision is not independent clinical validation. Local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K254013 by native exact submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, dental, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: PET or other nuclear-medicine radiopharmaceutical-distribution data with the labeled CT or supporting acquisition.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Receives PET DICOM through a medical device data system and returns enhanced DICOM while retaining the original images.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. Deployment details for the exact cleared configuration are not established in the public FDA decision material.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: Anatomical CT and functional nuclear-medicine images, attenuation correction, reconstructions, or processing outputs described in the exact FDA labeling.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Anatomical CT and functional nuclear-medicine images, attenuation correction, reconstructions, or processing outputs described in the exact FDA labeling.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Subtle Medical's current compliance page lists an annual SOC 2 Type II + HIPAA security audit, and ISO 13485:2016 (valid until 2027-07-12) and ISO/IEC 42001:2023 (valid until 2028-07-17) certificates. The page gives no audit period or report scope, and the SOC 2 report was not read.
Vendor-wide
Checked 2026-10-25
Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
Use by the qualified healthcare professionals identified for the exact labeled workflow; site-specific competency and training requirements remain to be established locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The software processes images and does not control the scanner; original and enhanced images must be distinguished, and clinical interpretation remains with the physician.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the evidence set; productivity or value claims require local evidence.
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes; exact monitoring thresholds and vendor commitments are unknown.
exact submission · checked 2026-09-04
Establish ownership for data quality, overrides, drift, incidents, recalls, and change control.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
11Source classes checked
0Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads
This submission was added after the prior exact-submission extraction and remains queued for source review. Exact FDA decision material was reviewed for identity and labeled use. Optional literature, trial, and recall candidates were not promoted without exact product or version applicability; commercial, security, and performance claims remain unknown where not established. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads remain unpublished until a human confirms the exact product and tested version.
Source classes: fda ai list, vendor product page, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, fda decision summary, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found in the evidence set. Obtain a written quote covering license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, downtime, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Deployment: Not verified - checked 2026-09-04 - Exact FDA submission
Deployment details for the exact cleared configuration are not established in the public FDA decision material.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Monitoring: Not verified - checked 2026-09-04 - Exact FDA submission
Post-deployment monitoring, drift thresholds, alerting, and revalidation commitments for the exact configuration require vendor and site confirmation.
Authorized purpose: uMI Panvivo variants acquire and display PET and CT information for anatomical and functional imaging, radiopharmaceutical distribution, attenuation correction, and the labeled body-region workflows.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body; brain; head and neck; heart; lung; breast; gastrointestinal; urinary; genital; and musculoskeletal anatomy
Authorized purpose: uMI Panvivo PET/CT acquires anatomical CT and functional PET images of radiopharmaceutical distribution for qualified diagnostic and treatment-planning workflows, including labeled lung-cancer-screening use.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body, head and neck, cardiac, and other labeled PET/CT regions
Authorized purpose: BIOGRAPH One with syngo MR XB10 combines metabolic or physiologic PET information with MR anatomy, MR-based attenuation correction, fused alignment, and support for treatment planning and interventions.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.